Abstract
The diagnostic performance of the widely-used Cervista HPV HR test was compared to the Hybrid Capture 2 (HC2) test in a Dutch population-based cervical cancer screening program. In 900 scrapings of women with normal cytomorphology, specificity was 90% (95%CI: 87.84-91.87) for the Cervista HPV HR test and 96% (95%CI: 94.76-97.37) for the HC2 test with 93% agreement between both tests (κ = 0.5, p<0.001). The sensitivity for CIN2+ using 65 scrapings of women with histological-confirmed CIN2+ was 91% (95%CI: 80.97-96.51) for the Cervista HPV HR test and 92% (95%CI: 82.94-97.43) for the HC2 test with 95% agreement between both tests (κ = 0.7, p<0.001). Fifty-seven of 60 HC2 negative/Cervista positive cases tested HPV-negative with PCR-based HPV assays; of these cases 56% were defined as Cervista triple-positive with FOZ values in all 3 mixes higher than the second cut-off of 1.93 (as set by manufacturer). By setting this cut-off at 5.0, specificity improved significantly without affecting sensitivity. External validation of this new cut-off at 5.0 in triple-positive scrapings of women selected from the SHENCCASTII database revealed that 22/24 histological normal cases now tested HPV-negative in the Cervista HPV HR test, while CIN2+ lesions remained HPV-positive. The intra-laboratory reproducibility of the Cervista HPV HR test (n = 510) showed a concordance of 92% and 93% for cut-off 1.93 and 5.0 (κ = 0.83 and κ = 0.84, p<0.001) and inter-laboratory agreement of the Cervista HPV HR test was 90% and 93% for cut-off 1.93 and 5.0 (κ = 0.80 and κ = 0.85, p<0.001). In conclusion, the specificity of the Cervista HPV HR test could be improved significantly by increasing the second cut-off from 1.93 to 5.0, without affecting the sensitivity of the test in a population-based screening setting.
Original language | English |
---|---|
Article number | 101930 |
Number of pages | 9 |
Journal | PLoS ONE |
Volume | 9 |
Issue number | 7 |
DOIs | |
Publication status | Published - 22-Jul-2014 |
Keywords
- HIGH-RISK HPV
- HUMAN-PAPILLOMAVIRUS DNA
- CERVICAL-CANCER
- WOMEN
- CYTOLOGY
- PERFORMANCE
- VALIDATION
- PREVENTION
- GUIDELINES
- EXPERIENCE
Fingerprint
Dive into the research topics of 'Comparing the Cervista HPV HR Test and Hybrid Capture 2 Assay in a Dutch Screening Population: Improved Specificity of the Cervista HPV HR Test by Changing the Cut-Off'. Together they form a unique fingerprint.Datasets
-
Dataset: Inter-laboratory agreement of the Cervista HPV HR test with a second cut-off at default setting of 1.93 (A) and at new setting of 5.0 (B)
Boers, A. (Creator), Slagter-Menkema, L. (Creator), van Hemel, B. (Creator), Belinson, J. L. (Creator), Ruitenbeek, T. (Creator), Buikema, H. (Creator), Klip, H. (Creator), Ghyssaert, H. (Creator), van der Zee, A. (Creator), de Bock, G. H. (Creator), Wisman, G. B. A. (Creator) & Schuuring, E. (Creator), University of Groningen, 22-Jul-2014
DOI: 10.1371/journal.pone.0101930.t006
Dataset